A comprehensive analysis of real-world data has challenged the long-held assumption that significant weight loss automatically translates to a more active lifestyle. The study, presented at the ENDO 2026 annual meeting, indicates that individuals utilizing Glucagon-like peptide-1 (GLP-1) receptor agonists—a class of drugs including blockbuster medications like semaglutide and tirzepatide—tended to log fewer daily steps and engage in less moderate-to-vigorous physical activity (MVPA) after beginning their treatment. Led by Dr. Sajana Maharjan of HSHS St. John’s Hospital in Springfield, Illinois, the research utilized data from the National Institutes of Health’s (NIH) "All of Us" Research Program, marking the first large-scale investigation to link wearable fitness tracker data with electronic health records for patients on these specific anti-obesity medications.
The findings come at a critical juncture in the global effort to manage obesity. While GLP-1 medications have demonstrated unprecedented efficacy in reducing body weight, clinical experts are increasingly concerned about the quality of that weight loss, specifically the simultaneous reduction of lean muscle mass alongside adipose tissue. Dr. Maharjan’s study highlights a potential "activity paradox," where patients becoming lighter does not necessarily correlate with them becoming more mobile or physically active. This revelation underscores the necessity of integrating structured exercise programs into the pharmacological management of obesity to mitigate the risks of muscle atrophy and metabolic slowing.
Methodology and the "All of Us" Research Program
The retrospective pre-post cohort study drew its power from the NIH’s "All of Us" Research Program, a longitudinal effort designed to gather health data from one million or more people living in the United States. A unique feature of this program is its ability to synchronize participants’ electronic health records (EHR) with data from consumer wearable devices, such as Fitbits. This integration allowed researchers to move beyond self-reported activity levels, which are often subject to recall bias, and instead utilize objective, minute-by-minute movement data.
The researchers initially identified 1,950 adults with obesity who had been prescribed a GLP-1 medication, including semaglutide (Ozempic/Wegovy), liraglutide (Saxenda), dulaglutide (Trulicity), or tirzepatide (Mounjaro/Zepbound). To ensure the integrity of the data, the team narrowed the focus to 753 individuals who possessed a sufficient volume of wearable-device data both before and after the initiation of the medication. The study cohort was predominantly female (78.6%) with a mean age of 52.7 years, representing a demographic that is frequently targeted for weight management interventions.
By comparing activity levels during the period immediately preceding the medication start date to the period following the commencement of treatment, the researchers were able to establish a clear trajectory of physical behavior. The primary metrics analyzed were the average daily step count and the total number of minutes spent in moderate-to-vigorous physical activity (MVPA) per day.
Detailed Findings: The Quantitative Decline in Activity
The results of the analysis revealed a statistically significant decrease in movement across the cohort. On average, the daily step count for participants dropped from 5,047 steps per day prior to treatment to 4,487 steps per day after starting a GLP-1 receptor agonist. This represents an approximately 11% reduction in total daily movement. Perhaps more concerning to public health officials was the decline in higher-intensity activity; MVPA minutes fell from an average of 28 minutes per day to 22 minutes per day, a 21% decrease.
The data further revealed that certain subgroups were more susceptible to this decline than others. The largest decreases in physical activity were observed among male participants and individuals who reported pre-existing joint or muscle pain. Conversely, factors such as the patient’s age, a history of heart failure, or a prior stroke did not significantly alter the trend, suggesting that the reduction in activity is a widespread phenomenon across various health profiles.
Crucially, the study found no evidence to support the hypothesis that weight loss achieved through these medications serves as a natural catalyst for increased exercise. While it is often theorized that as the "burden" of excess weight is lifted, patients will find movement easier and thus engage in it more frequently, the "All of Us" data suggests that pharmacological weight loss may actually be associated with a more sedentary lifestyle.
A Chronology of GLP-1 Development and the Rise of "Muscle Concern"
To understand the implications of Dr. Maharjan’s study, it is necessary to view it within the timeline of GLP-1 receptor agonist development. Originally developed in the early 2000s to treat Type 2 diabetes, the first GLP-1 drug, exenatide, was approved by the FDA in 2005. For over a decade, these drugs were primarily viewed through the lens of glycemic control. However, as researchers noted the significant weight loss side effects, the focus shifted toward obesity management.
- 2014: The FDA approved liraglutide (Saxenda) specifically for chronic weight management.
- 2021: The approval of semaglutide (Wegovy) for weight loss marked a turning point, as its efficacy approached levels previously only seen with bariatric surgery.
- 2023: Tirzepatide (Zepbound) received approval, further intensifying the public’s interest in "weight loss injections."
- 2024-2025: Emerging clinical data began to highlight the "sarcopenia" risk—the loss of muscle mass that often accompanies rapid weight loss. Medical journals began publishing concerns that up to 40% of the weight lost on GLP-1s could be lean muscle mass.
- 2026: Dr. Maharjan’s presentation at ENDO 2026 provides the first large-scale objective evidence that activity levels are actually decreasing during treatment, exacerbating the risk of muscle loss.
This timeline illustrates a shift from focusing solely on the scale to focusing on body composition. The medical community is moving from a "weight-centric" approach to a "health-centric" approach, where the preservation of muscle is viewed as being just as important as the loss of fat.
The Physiological and Psychological Implications
The decline in physical activity while on GLP-1 medications presents a multifaceted challenge. Physiologically, GLP-1 agonists work by slowing gastric emptying and signaling the brain to feel full. This often results in a significant caloric deficit. When the body is in a state of rapid weight loss and is not being stimulated by resistance training or consistent aerobic activity, it often catabolizes muscle tissue to meet its energy needs.
Dr. Maharjan emphasized that because these medications reduce both fat and lean muscle mass, physical activity is "essential for preserving strength and long-term health." Muscle mass is a primary driver of basal metabolic rate; losing it can lead to a metabolic plateau or rapid weight regain once medication is discontinued—a phenomenon sometimes referred to as "weight cycling" or "yo-yo dieting," which can be more harmful to cardiovascular health than maintaining a stable, higher weight.
Psychologically, the "effortless" nature of weight loss on GLP-1s may play a role. Patients who see the numbers on the scale drop rapidly without the need for strenuous exercise may feel less motivated to maintain a gym routine. Furthermore, the common side effects of GLP-1s—including nausea, fatigue, and gastrointestinal distress—may physically discourage patients from engaging in vigorous activity during the initial months of treatment.
Expert Reactions and the Call for Targeted Interventions
The presentation of this data at ENDO 2026 sparked immediate reactions from the endocrinology and sports medicine communities. Many experts believe the findings should serve as a "wake-up call" for prescribing physicians.
"While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise," Dr. Maharjan stated during her presentation. "The findings in our study reinforce that exercise cannot be optional for people taking these medications. People need targeted interventions that encourage physical activity alongside medication for obesity."
Medical professionals are now calling for a more integrated "Prescription Plus" model. In this framework, a prescription for a GLP-1 medication would be paired with a mandatory referral to a physical therapist or a certified strength and conditioning specialist. This ensures that as the patient loses weight, they are actively working to maintain the structural integrity of their musculoskeletal system.
Furthermore, some health systems are exploring the use of digital health platforms that link to the same wearable data used in the study. By monitoring a patient’s step counts and MVPA in real-time, clinicians can intervene early if they notice a significant drop in activity, providing coaching or adjusting the medication dosage to manage fatigue-inducing side effects.
Broader Impact on Public Health and Insurance
The implications of this study extend into the realms of public health policy and insurance coverage. As insurance providers grapple with the high costs of GLP-1 medications, there is an increasing push to ensure these drugs are being used in a way that produces long-term, sustainable health outcomes. If patients are losing muscle mass and becoming more sedentary, the long-term "health ROI" (return on investment) for insurers may be lower than expected, as these patients may remain at risk for falls, fractures, and metabolic disorders in their later years.
From a public health perspective, the study highlights a potential "sedentary trap" of modern medicine. As pharmaceutical solutions become more effective at treating the symptoms of lifestyle-related diseases, there is a risk that the foundational pillars of health—movement, nutrition, and sleep—may be de-emphasized. The "All of Us" data suggests that the "magic pill" (or injection) for obesity still requires the hard work of physical movement to achieve a truly healthy outcome.
Conclusion: Redefining Success in Obesity Treatment
The research presented by Dr. Maharjan and her team at HSHS St. John’s Hospital provides a necessary nuance to the success story of GLP-1 medications. While these drugs are undeniably powerful tools for weight reduction, they are not a substitute for physical activity. In fact, the data suggests that they may inadvertently lead to a more sedentary lifestyle, which, when combined with rapid weight loss, poses a threat to skeletal muscle health.
As the medical community moves forward, the definition of success in obesity treatment is likely to evolve. It will no longer be enough to simply track pounds lost; clinicians will need to monitor body composition, functional strength, and daily activity levels. The goal is not just a smaller patient, but a stronger, more active one. Dr. Maharjan’s study serves as a foundational piece of evidence in this evolution, proving that in the era of advanced pharmacology, the ancient wisdom of "movement as medicine" remains more relevant than ever. Future research will likely focus on which types of exercise—such as high-intensity interval training versus heavy resistance training—are most effective at counteracting the activity decline and muscle loss associated with GLP-1 therapy. For now, the message to patients and providers is clear: the medication starts the process, but movement sustains the health.
